中银国际:升维亚生物(1873.HK)目标价至4.87港元 重申“买入”评级
中银国际发表研究报告指,维亚生物(1873.HK)上半年录得收入1.42亿元人民币,按年上升83.9%,达成该行此前预测的全年收入68%。集团计划于2019下半年、2020年及2021年分别新增15、35及50个孵化/投资项目。该行上调维亚生物服务换现金(CFS)业务估值,并目标价由4.27港元,上调至4.87港元,重申“买入”投资评级。
中银国际表示,维亚生物基本面强劲,服务换现金业务收入及净利润分别按年增长72%及188%;服务换股权(EFS)业务收入及净利润同比分别上升128%及10%,主要因孵化项目的公平值变动。
另外,维亚生物回头客占CFS业务总收入82.7%,前十大客户贡献占比从去年同期51%下降到45%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.